一分钟看懂
这是一项关于淋巴瘤的III 期研究，登记的药物或干预包括Obinutuzumab；Glofitamab；Rituximab；Bendamustine；Lenalidomide；Tocilizumab，当前状态为招募中。登记地点显示中国北京、长春、成都、重庆等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Obinutuzumab；Glofitamab；Rituximab；Bendamustine；Lenalidomide；Tocilizumab · III 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Beijing Tong Ren Hospital, Capital Medical University · 北京
- The First Hospital of Jilin University · 长春
- West China Hospital of Sichuan University · 成都
- Chongqing Cancer Hospital · 重庆
- Fujian Provincial Cancer Hospital · 福州
- Sun yat-sen University Cancer Center · 广州
- Guangxi Cancer Hospital of Guangxi Medical University · 南宁
- Fudan University Shanghai Cancer Center · 上海
- The First Affiliated Hospital of China Medical University · 沈阳
- The First Affiliated Hospital of Wenzhou Medical University · 温州
- The First Affiliated Hospital of Zhengzhou University · 郑州
- Henan Cancer Hospital · 郑州
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- * Life expectancy at least 12 weeks
- * Histologically-confirmed MCL, with documentation of either overexpression of cyclin D1 or the presence of t(11:14) within 12 months of study entry
- * Relapsed (disease progression after the last treatment regimen) or refractory (failure to achieve a partial or complete response from the last treatment regimen) disease
- * At least 1 line of prior systemic therapy including a BTK inhibitor and additional systemic therapy option
- * Confirmed availability of tumor tissue, unless deemed unsafe per investigator assessment
- * At least one bi-dimensionally measurable (defined as at least 1.5 cm) nodal lesion, or one bi-dimensionally measurable (at least 1 cm) extranodal lesion, as measured on CT scan
- * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
- * Negative HIV test at screening
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06084936；登记信息更新于 2026-10-06；本站同步于 2026-10-08，中国中心当前名额未经人工确认。